HemOnc Today Current Issue

The following articles appeared in the print edition of HemOnc Today.

Table of Contents

• Success of abiraterone trials prompts ‘mind shift’ in prostate cancer treatment
• Completion lymph node dissection ‘not yet obsolete’ Vernon K. Sondak, MD
• ASCO presents value-based solutions to promote affordability, preserve innovation of cancer drugs
• Atlantic Health System Cancer Care appoints chief of hematology, oncology
• Be The Match appoints CEO
• Bristol-Myers Squibb, Clovis Oncology to evaluate nivolumab-rucaparib combination
• National Comprehensive Cancer Network appoints bladder cancer panel chairman
• Pembrolizumab fails to improve survival in head and neck squamous cell carcinoma
• Physician joins New York Cancer & Blood Specialists
• Prostate Cancer Foundation announces award recipients
• Society of Interventional Oncology elects officers, appoints board members
• Telephone-based intervention after lung cancer screening quadruples smoking cessation rates
• The University of Texas MD Anderson Cancer Center named best cancer hospital in nation
• The pathway to value: A complicated journey begins with one step John Sweetenham, MD, FRCP, FACP
• FDA allows marketing of test to help detect blood cancers
• FDA approves Idhifa for IDH2-mutated acute myeloid leukemia
• FDA approves Nerlynx for adjuvant treatment of HER-2-positive breast cancer
• FDA approves Vectibix for RAS wild-type metastatic colorectal cancer
• FDA clears expansion of cooling cap to reduce hair loss in patients with solid tumors
• FDA expands indication of Yervoy to include pediatric patients with melanoma
• Adjuvant chemoradiotherapy improves survival in nasopharyngeal carcinoma
• ASCO issues recommendations on second-line hormonal therapy for castration-resistant prostate cancer
• Biomarkers may guide personalized therapy for castration-resistant prostate cancer
• Definitions of clinical benefit differ between oncology society frameworks
• Emicizumab prophylaxis lowers bleeding rate in hemophilia A
• Experimental targeted therapy improves survival in acute myeloid leukemia
• FDA boxed warning reduces erythropoietin-stimulating agent use
• Genetic profiling feasible, useful in pediatric brain tumors
• Idarubicin dose escalation increases leukemia-free survival in AML
• Nivolumab, ipilimumab combination shows promise for renal cell carcinoma
• Opioid use common among cancer survivors
• Radiotherapy boost may reduce ipsilateral breast tumor recurrence in women with DCIS
• Reversion mutations may predict chemotherapy response in recurrent serous ovarian cancer
• Selumetinib fails to improve PFS in KRAS–mutant advanced NSCLC
• Sorafenib benefit dependent on hepatitis status in patients with HCC
• Standard surgery for melanoma with sentinel-node metastases does not extend survival
• Should oncologists recommend hormone therapy plus abiraterone for patients with nonmetastatic prostate cancer?